Aktien Sensor

Kyowa Kirin Co Ltd is a Japanese pharmaceutical powerhouse on the rise, driven by strategic investments, cutting-edge research, and innovative treatments that are expected to drive growth and strengthen its market position.

Kyowa Kirin and Amgen announce positive results from the ROCKET Phase 3 clinical trial program for rocatinlimab, a promising therapy for moderate to severe atopic dermatitis.

Kyowa Kirin Co Ltd has announced updates on its partnership with Kura Oncology, including upcoming presentations and submissions for rocatinlimab, a therapy targeting the OX40 receptor.